{"organizations": [], "uuid": "bde80571c800fbaf73f79ab0e657456ad5fa963c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-avadel-pharmaceuticals-reports-q1/brief-avadel-pharmaceuticals-reports-q1-adjusted-loss-per-share-0-34-idUSASC09YYO", "country": "US", "domain_rank": 408, "title": "BRIEF-Avadel Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.34", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-02T14:35:00.000+03:00", "replies_count": 0, "uuid": "bde80571c800fbaf73f79ab0e657456ad5fa963c"}, "author": "", "url": "https://www.reuters.com/article/brief-avadel-pharmaceuticals-reports-q1/brief-avadel-pharmaceuticals-reports-q1-adjusted-loss-per-share-0-34-idUSASC09YYO", "ord_in_thread": 0, "title": "BRIEF-Avadel Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.34", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-avadel pharmaceuticals reports", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "avadel pharmaceuticals plc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2, 2018 / 11:38 AM / Updated 5 minutes ago BRIEF-Avadel Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.34 Reuters Staff\nMay 2 (Reuters) - Avadel Pharmaceuticals PLC:\n* AVADEL PHARMACEUTICALS REPORTS FIRST QUARTER 2018 RESULTS * Q1 GAAP LOSS PER SHARE $0.32\n* Q1 REVENUE $33.3 MILLION VERSUS I/B/E/S VIEW $29.5 MILLION\n* Q1 EARNINGS PER SHARE VIEW $-0.27 â€” THOMSON REUTERS I/B/E/S * SEES FY 2018 REVENUE $105 MILLION TO $125 MILLION\n* AVADEL PHARMACEUTICALS - CASH AND MARKETABLE SECURITIES AT MARCH 31, 2018 WERE $198.2 MILLION, UP FROM $94.1 MILLION AT DECEMBER 31, 2017\n* AVADEL PHARMACEUTICALS - REITERATING FY 2018 GUIDANCE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-02T14:35:00.000+03:00", "crawled": "2018-05-02T15:29:39.013+03:00", "highlightTitle": ""}